Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the 7.5 mg step involves and how prescribers approach it
How prescribers actually decide whether 7.5 mg is right for you
The decision to move from 5 mg to 7.5 mg tirzepatide is a clinical judgement, not an automatic progression. Your prescriber weighs two things above all else: how well you tolerated the previous pen and whether side effects (most commonly nausea, loose stools or fatigue) have settled sufficiently. If 5 mg is still causing significant gastrointestinal discomfort, staying there longer is the safer, smarter call.
There is a common misconception worth addressing directly: that higher doses always produce faster results, and therefore that the goal should be to reach the highest dose as quickly as possible. Clinical practice does not support this. The titration schedule exists precisely to reduce the intensity of side effects by letting the body adjust incrementally. Rushing that process tends to increase dropout from treatment, not results.
NICE's appraisal of tirzepatide (TA1026) covers the full clinical picture, including the evidence base that informed the stepped-dose design. The broader question of which dose suits which patient is something our tirzepatide dose guide covers in detail. Suitability for a dose increase is also reviewed before every repeat at nume, a prescriber looks at your notes, not a form.
One practical point: if you are transferred from another service already on 7.5 mg, evidence of your current treatment is required before that dose is continued. A dose is not simply carried across automatically.
What the evidence tells us about this stage of treatment
The SURMOUNT-1 trial (involving 2,539 adults with obesity and no diabetes over 72 weeks) demonstrated that people using tirzepatide at the highest tolerated dose achieved average body-weight reductions of around 20–21% at 15 mg, with meaningful reductions appearing at intermediate doses too. The 7.5 mg pen is part of the titration pathway that builds to those outcomes, not a standalone endpoint, and individual results vary considerably.
What the trial also showed is that the therapeutic effect accumulates over time. Most participants had not reached maximum weight loss by the twelve-week mark; the curve continues for months. That context matters if you are at the 7.5 mg stage and wondering whether the treatment is working. Weight loss at this point may be more gradual than it was at the start, that is typical, not a sign of failure.
Side effects at 7.5 mg follow the same profile as the earlier doses: nausea, constipation, diarrhoea, indigestion and occasional fatigue. These are usually more noticeable in the first week or two after a dose step, then ease. Injection-site reactions are possible at any dose. If you experience severe, persistent stomach pain that reaches the back, with or without vomiting, seek medical attention promptly, this warrants urgent assessment to rule out pancreatitis. You can report any suspected side effects through the MHRA Yellow Card scheme.
Anyone who is pregnant, trying to conceive, or breastfeeding should not use tirzepatide. The medicine is not licensed for people under 18.
Reaching 7.5 mg via the NHS versus private treatment
On the NHS, tirzepatide is being rolled out in phases under NICE TA1026, and access is currently limited to people meeting specific BMI and comorbidity thresholds, the criteria tightened considerably in the early cohorts. Even where someone qualifies, progressing through the dose schedule happens within the NHS service and is managed by that service's clinicians.
Private treatment works differently. There is no referral needed and no waiting list, but the clinical rigour around dose increases is the same. At nume, each repeat order is reviewed by a GPhC-registered Independent Prescriber before dispatch, a real person reading your notes and confirming that the next step is appropriate. If you are considering what private treatment costs at this stage, the Mounjaro price comparison page sets out what to look for and what a transparent price should include.
For anyone earlier in the schedule curious about the preceding step, the tirzepatide 5 mg page covers what that dose involves and when a prescriber might consider moving forward.
What moving to 7.5 mg means in practice
From a day-to-day standpoint, the 7.5 mg pen is used exactly like the earlier ones: a once-weekly subcutaneous injection into the abdomen, thigh or upper arm, rotating sites each week. The pen format does not change. Storage remains the same, refrigerated between 2–8°C; the exact room-temperature window for travel is in the Patient Information Leaflet and should be followed precisely.
People sometimes ask whether they should adjust what they eat differently at this dose. Appetite suppression often deepens as the dose increases, which can make it easier to reduce portions but also raises the importance of eating enough protein and staying well hydrated, and if you want to understand how this compares with tirzepatide 2.5 mg weight loss at the starting dose, that page explains what the early weeks typically look like. Any specific dietary guidance should come from your prescriber or a registered dietitian, not a dose page. What does not change at 7.5 mg is the expectation to maintain the lifestyle elements (reduced-calorie eating and regular activity) that the medicine is licensed to support alongside.
The Mounjaro treatment overview explains the full licensed schedule, how the dual GIP and GLP-1 mechanism works, and what to expect across the course of treatment. If you have questions about your own treatment, our support team is available seven days a week. And if you are not yet started and want to understand whether this pathway suits you, a free consultation with our prescribers is the right starting point, including for those looking ahead to what tirzepatide 10 mg involves at the next stage of the schedule.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.